Benign prostatic hyperplasia: Treatment in primary care

British Medical Journal

Volumn 333, Issue 7567, 2006, Pages 535-539

  Patel, Anand K ^a   Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; DOXAZOSIN; DUTASTERIDE; ENALAPRIL; FINASTERIDE; NIFEDIPINE; SILDENAFIL; STEROID 5ALPHA REDUCTASE; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

ALTERNATIVE MEDICINE; ASTHENIA; BLADDER OBSTRUCTION; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIZZINESS; EJACULATION DISORDER; GYNECOMASTIA; HEADACHE; HUMAN; HYPERTENSION; LIBIDO DISORDER; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 33748795811     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38946.616551.BE1     Document Type: Review

References (22)

1. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54.
2. Chapple C, Artibani W, Berges R, Kaplan S, Michel M, Perrin P, et al. New medical developments in the management of LUTS in adult men (World Health Organization report, committee 6). In: McConnel J, Abrams P, Denis L, Khoury S, Roehrborn C, eds. Male lower urinary tract dysfunction. Jersey: Health Publications, 2006:143-94.
3. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 2005;95(suppl 4):29-36.
4. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJC Int 2005;95(suppl 4):12-8.
5. Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system, BJU Int 2005;95(suppl 4);19-28.
6. Van Keirehrocck P, Jardin A, van Cangh P, Laval KU. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002;41:54-60; discussion: I.
7. Lowe FC, Olson PJ, Padley RJ. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Urology 1999;54:81-5.
8. Chapple CR, Baert L, Thind P, Hofner K, Khoe GS, Spangberg A. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997;32:462-70.
9. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997;19:730-42.
10. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR. et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:19:15-40.
11. Chapple CR. The oral controlled absorption system (OCAS(R)): the evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Eur Urol Suppl 2005;4:20-2.
12. Crawford ED. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 2005;95(suppl 1):1-5.
13. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73.
14. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.
15. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004;93:985-90.
16. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002;2:14.
17. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709-15.
18. GlaxoSmithKline trial registration website. Study No: ARI40001, year 1. Last updated 22 December 2004. http://ctr.gsk.co.uk/Summary/dutasteride/ studylist.asp (last accessed 18 Jul 2006).
19. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology 2000;56:610-6.
20. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and comhination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
21. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004;94:738-44.
22. National Institute for Clinical Excellence. Clinical guidelines and referral protocols-referral practice: a guide to appropriate referral from general to specialist services. London: NICE, May 2000.